C'est la date fixée pour la prochaine rencontre, qui pourrait donc voir se terminer la phase 1 de la procédure Renault. Le nombre de pertes d'emploi n'est pas encore déterminé de manière ...

Commercialisé depuis septembre 2022, le Renault Austral avait inauguré le nouveau tournant stylistique de Renault. Mais comme ...

More than 30 years after Renault invented ... output levels: a 1.6-litre diesel with 128bhp or 158bhp, and a 197bhp 1.6 petrol. However, only the two more powerful Espace models have the smooth ...

Si la Phase 1 date de 2015, la phase 2 de l’Espace ... Points forts pour le Renault Espace La grande question demeure donc de déterminer, si oui ou non l’Espace a plus de points forts ...

Renault has no plans to sell the fifth-generation Espace in the UK. However, if the holiday rent-a-car rep offers you a choice of petrol or diesel, we’d pick the oil burner every time.

It’s the kind of clever thinking we love about the most radical Renaults – including the original Espace ... the so-called Phase Two cars are easier to tame. In 1993, Renault wanted to ...

Press release_Renault Group_2024 H1 Results 2024 first half resultsRenault Group breaks new records and continues to improve ...

Why buy a used Renault Grand Espace? The Renault Grand Espace is the long wheelbase version of the standard Espace, providing more comfort and space in this seven seater for people and luggage. If you ...

Grâce à une stratégie gagnante en Europe 1 (+6,7 %), Renault ... à particuliers. Renault accélère également en Europe sa ...

Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda.

A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19 ...

In the Phase 1/1b clinical trial, ficerafusp alfa in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity, with a 64% overall response rate (ORR), 18% complete ...